998 resultados para Prostate carcinoma
Resumo:
The hypoxia inducible factor 1 alpha (HIF1a) is a key regulator of tumour cell response to hypoxia, orchestrating mechanisms known to be involved in cancer aggressiveness and metastatic behaviour. In this study we sought to evaluate the association of a functional genetic polymorphism in HIF1A with overall and metastatic prostate cancer (PCa) risk and with response to androgen deprivation therapy (ADT). The HIF1A +1772 C>T (rs11549465) polymorphism was genotyped, using DNA isolated from peripheral blood, in 1490 male subjects (754 with prostate cancer and 736 controls cancer-free) through Real-Time PCR. A nested group of cancer patients who were eligible for androgen deprivation therapy was followed up. Univariate and multivariate models were used to analyse the response to hormonal treatment and the risk for developing distant metastasis. Age-adjusted odds ratios were calculated to evaluate prostate cancer risk. Our results showed that patients under ADT carrying the HIF1A +1772 T-allele have increased risk for developing distant metastasis (OR, 2.0; 95%CI, 1.1-3.9) and an independent 6-fold increased risk for resistance to ADT after multivariate analysis (OR, 6.0; 95%CI, 2.2-16.8). This polymorphism was not associated with increased risk for being diagnosed with prostate cancer (OR, 0.9; 95%CI, 0.7-1.2). The HIF1A +1772 genetic polymorphism predicts a more aggressive prostate cancer behaviour, supporting the involvement of HIF1a in prostate cancer biological progression and ADT resistance. Molecular profiles using hypoxia markers may help predict clinically relevant prostate cancer and response to ADT.
Resumo:
Existem vários métodos de Imagem que permitem avaliar a mama. Estes métodos têm conhecido uma evolução importante, quer por melhoria de técnicas como a mamografia, ecografia e Ressonância Magnética, quer pelo aparecimento de novas técnicas, como a tomossíntese. Os autores abordam as diferentes técnicas de Imagem da mama, as suas indicações e características, bem como alguns aspectos tecnológicos que correspondem a melhorias recentes.
Resumo:
Chronic infection by hepatitis C virus (HCV) is one of the main risk factors for the development of liver cirrhosis and hepatocellular carcinoma. However, the emergence of hepatocellular carcinoma (HCC) in non-cirrhotic HCV patients, especially after sustained virological response (SVR) is an unusual event. Recently, it has been suggested that HCV genotype 3 may have a particular oncogenic mechanism, but the factors involved in these cases as well as the profile of these patients are still not fully understood. Thus, we present the case of a non-cirrhotic fifty-year-old male with HCV infection, genotype 3a, who developed HCC two years after treatment with pegylated-interferon and ribavirin, with SVR, in Brazil.
Resumo:
The hypoxia inducible factor 1 alpha (HIF1a) is a key regulator of tumour cell response to hypoxia, orchestrating mechanisms known to be involved in cancer aggressiveness and metastatic behaviour. In this study we sought to evaluate the association of a functional genetic polymorphism in HIF1A with overall and metastatic prostate cancer (PCa) risk and with response to androgen deprivation therapy (ADT). The HIF1A +1772 C>T (rs11549465) polymorphism was genotyped, using DNA isolated from peripheral blood, in 1490 male subjects (754 with prostate cancer and 736 controls cancer-free) through Real-Time PCR. A nested group of cancer patients who were eligible for androgen deprivation therapy was followed up. Univariate and multivariate models were used to analyse the response to hormonal treatment and the risk for developing distant metastasis. Age-adjusted odds ratios were calculated to evaluate prostate cancer risk. Our results showed that patients under ADT carrying the HIF1A +1772 T-allele have increased risk for developing distant metastasis (OR, 2.0; 95%CI, 1.1-3.9) and an independent 6-fold increased risk for resistance to ADT after multivariate analysis (OR, 6.0; 95%CI, 2.2-16.8). This polymorphism was not associated with increased risk for being diagnosed with prostate cancer (OR, 0.9; 95%CI, 0.7-1.2). The HIF1A +1772 genetic polymorphism predicts a more aggressive prostate cancer behaviour, supporting the involvement of HIF1a in prostate cancer biological progression and ADT resistance. Molecular profiles using hypoxia markers may help predict clinically relevant prostate cancer and response to ADT.
Resumo:
Merkel cell carcinoma (MCC) is a rare malignant and primary neuroendocrine carcinoma with several known risk factors. Early diagnosis and aggressive treatment are critical. We report the case of an 82-year old woman with a Merkel cell carcinoma on the face. Clinical and histopathological features are presented. In addition, dermoscopic features and the differential diagnosis of this rare tumor are discussed. Although nodules with atypical dermoscopic vascular pattern and milky-red areas will end up being excised, this report adds more clues to the rarely described dermoscopic morphologic presentation of MCC.
Resumo:
BACKGROUND: Few randomised studies have compared antiandrogen intermittent hormonal therapy (IHT) with continuous maximal androgen blockade (MAB) therapy for advanced prostate cancer (PCa). OBJECTIVE: To determine whether overall survival (OS) on IHT (cyproterone acetate; CPA) is noninferior to OS on continuous MAB. DESIGN, SETTING, AND PARTICIPANTS: This phase 3 randomised trial compared IHT and continuous MAB in patients with locally advanced or metastatic PCa. INTERVENTION: During induction, patients received CPA 200 mg/d for 2 wk and then monthly depot injections of a luteinising hormone-releasing hormone (LHRH; triptoreline 11.25 mg) analogue plus CPA 200 mg/d. Patients whose prostate-specific antigen (PSA) was <4 ng/ml after 3 mo of induction treatment were randomised to the IHT arm (stopped treatment and restarted on CPA 300 mg/d monotherapy if PSA rose to ≥20 ng/ml or they were symptomatic) or the continuous arm (CPA 200 mg/d plus monthly LHRH analogue). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary outcome measurement was OS. Secondary outcomes included cause-specific survival, time to subjective or objective progression, and quality of life. Time off therapy in the intermittent arm was recorded. RESULTS AND LIMITATIONS: We recruited 1045 patients, of which 918 responded to induction therapy and were randomised (462 to IHT and 456 to continuous MAB). OS was similar between groups (p=0.25), and noninferiority of IHT was demonstrated (hazard ratio [HR]: 0.90; 95% confidence interval [CI], 0.76-1.07). There was a trend for an interaction between PSA and treatment (p=0.05), favouring IHT over continuous therapy in patients with PSA ≤1 ng/ml (HR: 0.79; 95% CI, 0.61-1.02). Men treated with IHT reported better sexual function. Among the 462 patients on IHT, 50% and 28% of patients were off therapy for ≥2.5 yr or >5 yr, respectively, after randomisation. The main limitation is that the length of time for the trial to mature means that other therapies are now available. A second limitation is that T3 patients may now profit from watchful waiting instead of androgen-deprivation therapy. CONCLUSIONS: Noninferiority of IHT in terms of survival and its association with better sexual activity than continuous therapy suggest that IHT should be considered for use in routine clinical practice.
Resumo:
Os AA estudaram retrospectivamente os processos clínicos de 370 doentes com carcinoma da próstata, com o intuito de dar uma ideia da problemática desta doença em Portugal. Ressalvando o facto de a análise incidir sobre casos tratados por vários urologistas e não haver assim uniformidade nos critérios, são apresentadas sucessivamente as manifestações clínicas, métodos de diagnóstico presumível e definitivo e a terapêutica instituída. Apontam ainda a mortalidade, no país, nos últimos anos, por carcinoma da próstata e por tumores malignos em geral e apresentam uma tabela em que aquela é comparada com a de outros países.
Resumo:
O carcinoma lobular invasivo (CLI) representa 5-15% dos casos de cancro invasivo da mama, diferindo do carcinoma ductal invasivo(CDI), o tumor invasivo mais frequente da mama, quer na forma de apresentação clínica, quer nos aspectos imagiológicos e histológicos, assim como no padrão de metastização. O objectivo deste artigo passa pelo relato clínico de um padrão atípico de metastização de cancro da mama. Mulher de 80 anos, que apresentava queixas de dor abdominal, com 6 meses de evolução, de carácter generalizado, com maior intensidade nos quadrantes direitos, associada a episódios de sub-oclusão. O exame objectivo revelou volumosa hérnia incisional paramediana direita sem sinais de sofrimento e uma lesão ulcerada da mama esquerda nunca antes revelada pela doente. Realizou uma mamografia que mostrou uma lesão T4 e a biópsia da mesma revelou Carcinoma Ductal Invasivo. Por apresentar anemia microcítica hipocrómica de 7 g/dL realizou também uma Endoscopia Digestiva Alta que demonstrou uma úlcera da pequena curvatura gástrica cuja biópsia revelou um carcinoma difuso. Optou-se pela intervenção cirúrgica com ideação paliativa. Foi efectuada mastectomia simples esquerda e correcção de hérnia incisional com enterectomia segmentar. Os resultados histológicos das peças operatórias foram surpreendentes: Carcinoma lobular invasivo da mama e metástase do mesmo no segmento de intestino ressecado. Foram revistas as lâminas referentes à biópsia gástrica previamente realizada, tendo sido feito estudo imunohistoquímico que mostrou positividade para os receptores hormonais o que favorecia tratar-se de metástase de carcinoma lobular da mama no estômago. Como conclusão temos a referir que o CLI apresenta um padrão distinto de metastização em relação ao CDI, com diferentes órgãos-alvo, realçando o papel fundamental da suspeição clínica e de uma histologia exigente para o seu diagnóstico.
Resumo:
Os autores analisam os processos clínicos dos doentes com carcinoma do pulmão, internados no Serviço 1 de Medicina do Hospital de Santo António dos Capuchos, num período de 12 anos (1978-1989). Dos 112 doentes considerados, 50% tinham confirmação histológica, os restantes tinham forte evidência clínico-radiológica, endoscópica e/ou necrópsica ou pesquisa positiva de células neoplásicas na expectoração, secreções brônquicas ou no líquido pleural. Apresentam-se os aspectos clínicos, meios complementares de diagnóstico utilizados, e realça-se o estado geralmente avançado da doença, a dificuldade do seu diagnóstico histológico e a elevada mortalidade (55,4%).
Resumo:
Multiparametric Magnetic Resonance Imaging has been increasingly used for detection, localization and staging of prostate cancer over the last years. It combines high-resolution T2 Weighted-Imaging and at least two functional techniques, which include Dynamic Contrast–Enhanced Magnetic Resonance Imaging, Diffusion-Weighted Imaging, and Magnetic Resonance Imaging Spectroscopy. Although the combined use of a pelvic phased-array and an Endorectal Coil is considered the state-of-the-art for Magnetic Resonance Imaging evaluation of prostate cancer, Endorectal Coil is only absolute mandatory for Magnetic Resonance Imaging Spectroscopy at 1.5 T. Sensitivity and specificity levels in cancer detection and localization have been improving with functional technique implementation, compared to T2 Weighted-Imaging alone. It has been particularly useful to evaluate patients with abnormal PSA and negative biopsy. Moreover, the information added by the functional techniques may correlate to cancer aggressiveness and therefore be useful to select patients for focal radiotherapy, prostate sparing surgery, focal ablative therapy and active surveillance. However, more studies are needed to compare the functional techniques and understand the advantages and disadvantages of each one. This article reviews the basic principles of prostatic mp-Magnetic Resonance Imaging, emphasizing its role on detection, staging and active surveillance of prostate cancer.
Resumo:
A nefrectomia radical associada a trombectomia da veia cava inferior constitui a única opção terapêutica passível de melhoria prognóstica dos carcinomas de células renais com trombos venosos major. Descrevemos o caso de um homem, 55 anos, com o diagnóstico de tumor renal com trombo intra-cávico de grandes dimensões. O doente foi alvo de uma abordagem multidisciplinar, tendo sido submetido a nefrectomia radical à direita, trombectomia e cavoplastia, com recurso ainda a bypass cardiopulmonar e circulação extra-corpórea. O pós-operatório não registou intercorrências. A análise histológica concluiu tratar-se de um carcinoma de células renais, variante células claras e trombo excisado na totalidade, sem invasão da parede venosa. Aos dois anos de pós-operatório o doente encontra-se sem evidência de recidiva tumoral nem foram descritos eventos de embolização pulmonar.
Resumo:
The use of multiparametric magnetic resonance imaging (mp-MRI) for prostate cancer has increased over recent years, mainly for detection, staging, and active surveillance. However, suspicion of recurrence in the set of biochemical failure is becoming a significant reason for clinicians to request mp-MRI. Radiologists should be able to recognize the normal post-treatment MRI findings. Fibrosis and atrophic remnant seminal vesicles after prostatectomy are often found and must be differentiated from local relapse. Moreover, brachytherapy, external beam radiotherapy, cryosurgery, and hormonal therapy tend to diffusely decrease the signal intensity of the peripheral zone on T2-weighted images (T2WI) due to the loss of water content, consequently mimicking tumor and hemorrhage. The combination of T2WI and functional studies like diffusion-weighted imaging and dynamic contrast-enhanced improves the identification of local relapse. Tumor recurrence tends to restrict on diffusion images and avidly enhances after contrast administration either within or outside the gland. The authors provide a pictorial review of the normal findings and the signs of local tumor relapse after radical prostatectomy, external beam radiotherapy, brachytherapy, cryosurgery, and hormonal therapy.
Resumo:
Analisa-se, em material de necropsias, a ocorrência de carcinoma esofágico em não-chagásicos e em chagásicos com e sem megaesôfago. Observou-se um aumento altamente significativo da freqüência do carcinoma de esôfago associado ao megaesôfago, em relação aos controles e aos chagásicos sem megaesôfago. A associação entre carcinoma esofágico e infecção chagásica não foi estatisticamente significativa.